Hims & Hers Health Inc.(HIMS)股价10月14日盘前大涨5.4%,因市场预期FDA将重新审视禁止这家远程医疗公司销售降糖药物的决定。
根据新闻报道,FDA表示将重新考虑禁止制药商销售礼来公司减肥药和糖尿病药自制版本的决定。这意味着像HIMS这样的远程医疗公司或可获准继续提供这些药物。
此外,FDA还将Tirzepatide这种处方级减肥药从短缺名单中删除。这一药品是HIMS竞争对手诺和诺德公司Wegovy药物的主要成分,恢复供应或给远程医疗公司带来新的商机。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.